Biogen shares dipped 2% then bounced back 5% this week after the company on Wednesday presented long-term Phase III data of its controversial yet approved Alzheimer’s disease drug Aduhelm (aducanumab) at AD/PD 2022. After 128 weeks of treatment, patients in the long-term extension phase of two Phase III trials continued showing “significant” reductions in amyloid beta plaques and plasma p-tau181 . . .
The post StockWatch: Biogen Stays Flat Despite Positive 128-Week Aduhelm Data appeared first on GEN – Genetic Engineering and Biotechnology News.